BackGinkgo Bioworks Holdings Overview

Ginkgo Bioworks Holdings Total Liabilities

Track Ginkgo Bioworks Holdings's total liabilities ($570M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$569.76M
7.81% YoYΔ $-48.30M vs prior year quarter

Peer average

Loading

Ginkgo Bioworks Holdings Total Liabilities History

Loading

Ginkgo Bioworks Holdings vs. peers: Total Liabilities Comparison

Loading

Ginkgo Bioworks Holdings Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Ginkgo Bioworks Holdings (DNA) FAQ

Ginkgo Bioworks Holdings's total liabilities stands at $570M as of June 2026. That compares with $620M in the prior-year period — down 7.8% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Ginkgo Bioworks Holdings reported $570M in total liabilities versus $620M a year earlier — a 7.8% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $620M in the prior-year period — down 7.8% year over year. Sustained growth in total liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Ginkgo Bioworks Holdings's total liabilities evolved across reporting periods, while the comparison chart places DNA next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total liabilities is commonly used to spot outliers. Ginkgo Bioworks Holdings's reading of $570M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.